Sino Biopharmaceutical Management
Management criteria checks 2/4
Sino Biopharmaceutical's CEO is Eric Tse, appointed in Jul 2022, has a tenure of 6.75 years. total yearly compensation is CN¥64.52M, comprised of 35.7% salary and 64.3% bonuses, including company stock and options. directly owns 22.77% of the company’s shares, worth $2.77B. The average tenure of the management team and the board of directors is 0.4 years and 8 years respectively.
Key information
Eric Tse
Chief executive officer
CN¥64.5m
Total compensation
| CEO salary percentage | 35.67% |
| CEO tenure | 4yrs |
| CEO ownership | 22.8% |
| Management average tenure | less than a year |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | CN¥65m | CN¥23m | CN¥2b |
| Sep 30 2025 | n/a | n/a | CN¥3b |
| Jun 30 2025 | n/a | n/a | CN¥4b |
| Mar 31 2025 | n/a | n/a | CN¥3b |
| Dec 31 2024 | CN¥51m | CN¥23m | CN¥2b |
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥50m | CN¥23m | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥1b |
| Mar 31 2023 | n/a | n/a | CN¥2b |
| Dec 31 2022 | n/a | n/a | CN¥2b |
| Sep 30 2022 | n/a | n/a | CN¥5b |
| Jun 30 2022 | n/a | n/a | CN¥8b |
| Mar 31 2022 | n/a | n/a | CN¥14b |
| Dec 31 2021 | CN¥23m | CN¥6m | CN¥15b |
| Sep 30 2021 | n/a | n/a | CN¥12b |
| Jun 30 2021 | n/a | n/a | CN¥10b |
| Mar 31 2021 | n/a | n/a | CN¥4b |
| Dec 31 2020 | CN¥25m | CN¥7m | CN¥3b |
| Sep 30 2020 | n/a | n/a | CN¥2b |
| Jun 30 2020 | n/a | n/a | CN¥3b |
| Mar 31 2020 | n/a | n/a | CN¥3b |
| Dec 31 2019 | CN¥6m | CN¥870k | CN¥3b |
Compensation vs Market: Eric's total compensation ($USD9.53M) is below average for companies of similar size in the US market ($USD14.60M).
Compensation vs Earnings: Eric's compensation has increased by more than 20% in the past year.
CEO
Eric Tse (30 yo)
Mr. S. Y. Tse, also known as Eric, serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairwoman of the Board | 11.1yrs | CN¥36.86m | 0.044% $ 5.3m | |
| CEO & Executive Director | 4yrs | CN¥64.52m | 22.77% $ 2.8b | |
| Founder & Senior Executive Vice Chairman | 5.9yrs | CN¥44.90m | 9.52% $ 1.2b | |
| Executive Vice Chairwoman of the Board | 9.3yrs | CN¥39.39m | 16.7% $ 2.0b | |
| Senior VP & Executive Director | no data | CN¥4.59m | 2.03% $ 246.0m | |
| Vice President of Public Affairs & ESG | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Head of Clinical Development for Chronic Diseases | less than a year | no data | no data | |
| Head of Clinical Development for Autoimmune Diseases | less than a year | no data | no data | |
| Company Secretary | less than a year | no data | no data |
Experienced Management: SBMF.F's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairwoman of the Board | 11.1yrs | CN¥36.86m | 0.044% $ 5.3m | |
| CEO & Executive Director | 6.8yrs | CN¥64.52m | 22.77% $ 2.8b | |
| Founder & Senior Executive Vice Chairman | 5.9yrs | CN¥44.90m | 9.52% $ 1.2b | |
| Executive Vice Chairwoman of the Board | 9.3yrs | CN¥39.39m | 16.7% $ 2.0b | |
| Senior VP & Executive Director | no data | CN¥4.59m | 2.03% $ 246.0m | |
| Independent Non-Executive Director | 20.7yrs | CN¥383.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 11.3yrs | CN¥383.00k | no data | |
| Independent Non-Executive Director | 11.3yrs | CN¥349.00k | no data | |
| Independent Non-Executive Director | 5.6yrs | CN¥383.00k | 0.00040% $ 48.6k | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: SBMF.F's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 14:16 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sino Biopharmaceutical Limited is covered by 36 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Bo Yu | China International Capital Corporation Limited |